Serveur d'exploration SRAS

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Fighting against infectious diseases in China.

Identifieur interne : 002432 ( Ncbi/Curation ); précédent : 002431; suivant : 002433

Fighting against infectious diseases in China.

Auteurs : Weidong Yin [République populaire de Chine]

Source :

RBID : pubmed:22185808

Descripteurs français

English descriptors

Abstract

Dr. Yin started his research on infectious disease prevention in the 1980s. In 1985, Dr. Yin sucessfully isolated the hepatitis A virus, after which, in 2002, he developed the first proprietary inactivated hepatitis A vaccine in China and soon launched it into the China market. Led by Dr. Yin, Sinovac successfully developed the vaccine prducts against SARS, H5N1, H1N1, hepatitis A and B and infleunza. Currently, Sinovac is working on the R&D of EV71 vaccine against hand, foot and mouth disease, and pneumococcal conjugate vaccine. Sinovac aims to provide Chinese children with international quality vaccines, and provide children in the world with vaccines made in China.

DOI: 10.4161/hv.7.12.18971
PubMed: 22185808

Links toward previous steps (curation, corpus...)


Links to Exploration step

pubmed:22185808

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Fighting against infectious diseases in China.</title>
<author>
<name sortKey="Yin, Weidong" sort="Yin, Weidong" uniqKey="Yin W" first="Weidong" last="Yin">Weidong Yin</name>
<affiliation wicri:level="3">
<nlm:affiliation>Sinovac, Beijing, China. yinwd@sinovac.com</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Sinovac, Beijing</wicri:regionArea>
<placeName>
<settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2011">2011</date>
<idno type="RBID">pubmed:22185808</idno>
<idno type="pmid">22185808</idno>
<idno type="doi">10.4161/hv.7.12.18971</idno>
<idno type="wicri:Area/PubMed/Corpus">001428</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001428</idno>
<idno type="wicri:Area/PubMed/Curation">001428</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001428</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001396</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001396</idno>
<idno type="wicri:Area/Ncbi/Merge">002432</idno>
<idno type="wicri:Area/Ncbi/Curation">002432</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Fighting against infectious diseases in China.</title>
<author>
<name sortKey="Yin, Weidong" sort="Yin, Weidong" uniqKey="Yin W" first="Weidong" last="Yin">Weidong Yin</name>
<affiliation wicri:level="3">
<nlm:affiliation>Sinovac, Beijing, China. yinwd@sinovac.com</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Sinovac, Beijing</wicri:regionArea>
<placeName>
<settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series>
<title level="j">Human vaccines</title>
<idno type="eISSN">1554-8619</idno>
<imprint>
<date when="2011" type="published">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Child</term>
<term>China (epidemiology)</term>
<term>Communicable Disease Control</term>
<term>Hepatitis A virus (immunology)</term>
<term>Humans</term>
<term>Influenza A Virus, H1N1 Subtype (immunology)</term>
<term>Influenza A Virus, H5N1 Subtype (immunology)</term>
<term>Research</term>
<term>SARS Virus (immunology)</term>
<term>Vaccines, Inactivated</term>
<term>Viral Vaccines</term>
<term>Virus Diseases (prevention & control)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Chine (épidémiologie)</term>
<term>Contrôle des maladies contagieuses</term>
<term>Enfant</term>
<term>Humains</term>
<term>Maladies virales ()</term>
<term>Recherche</term>
<term>Sous-type H1N1 du virus de la grippe A (immunologie)</term>
<term>Sous-type H5N1 du virus de la grippe A (immunologie)</term>
<term>Vaccins antiviraux</term>
<term>Vaccins inactivés</term>
<term>Virus de l'hépatite A (immunologie)</term>
<term>Virus du SRAS (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en">
<term>Vaccines, Inactivated</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en">
<term>China</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr">
<term>Sous-type H1N1 du virus de la grippe A</term>
<term>Sous-type H5N1 du virus de la grippe A</term>
<term>Virus de l'hépatite A</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en">
<term>Hepatitis A virus</term>
<term>Influenza A Virus, H1N1 Subtype</term>
<term>Influenza A Virus, H5N1 Subtype</term>
<term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en">
<term>Virus Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr">
<term>Chine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Child</term>
<term>Communicable Disease Control</term>
<term>Humans</term>
<term>Research</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Contrôle des maladies contagieuses</term>
<term>Enfant</term>
<term>Humains</term>
<term>Maladies virales</term>
<term>Recherche</term>
<term>Vaccins antiviraux</term>
<term>Vaccins inactivés</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr">
<term>République populaire de Chine</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Dr. Yin started his research on infectious disease prevention in the 1980s. In 1985, Dr. Yin sucessfully isolated the hepatitis A virus, after which, in 2002, he developed the first proprietary inactivated hepatitis A vaccine in China and soon launched it into the China market. Led by Dr. Yin, Sinovac successfully developed the vaccine prducts against SARS, H5N1, H1N1, hepatitis A and B and infleunza. Currently, Sinovac is working on the R&D of EV71 vaccine against hand, foot and mouth disease, and pneumococcal conjugate vaccine. Sinovac aims to provide Chinese children with international quality vaccines, and provide children in the world with vaccines made in China.</div>
</front>
</TEI>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002432 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 002432 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    Ncbi
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:22185808
   |texte=   Fighting against infectious diseases in China.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i   -Sk "pubmed:22185808" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1 

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021